Clinton Foundation HIV/AIDS Initiative (CHAI) has signed an agreement with Guava Technologies that can reduce the cost of CD4 testing by up to 50%. Since the HIV virus destroys the CD4 cells leaving people more susceptible to infection, CD4 tests are used to measure the number of functioning CD4 cells to help determine when antiretrovirals (ARVs) should be administered, when a patient’s regimen should change and when ARV therapy should be stopped.

Under the agreement, Guava Technologies will offer its CD4 System at a discounted price to the members of CHAI’s Procurement Consortium, a coalition of 56 developing countries around the world including 27 countries across the African continent.

Previous articleStudy Shows Biomarker in Blood Can Predict Sickle Cell Disease Complication
Next articleGenentech and Inotek to Develop PARP Inhibitors for Cancer